PPARs: History and advances

Methods in Molecular Biology

Volumn 952, Issue , 2013, Pages 1-6

  Youssef, Jihan ^a   Badr, Mostafa Z ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Peroxisome proliferators; PPARs; PPRE; RXRs; TZDs

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL; ARTICLE; CHEMISTRY; HISTORY; HUMAN; METABOLISM; RESEARCH;

ANIMALS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RESEARCH;

EID: 84870479754     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-155-4_1     Document Type: Article

References (40)

1. Lalwani ND et al (1983) Detection of a nafenopin binding protein in rat liver cytosol associated with induction of peroxisome proliferation by hypolipidemic compounds. Biochem Biophys Res Commun 116:388-393
2. Lalwani ND et al (1987) Peroxisome proliferator-binding protein: Identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proc Natl Acad Sci USA 84: 5242-5246
3. Alvares K et al (1990) Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP70 family. Proc Natl Acad Sci USA 87:5293-5297
4. Isseman I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650
5. Gottlicher M et al (1992) Fatty acids activate chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89:4653-4657
6. Schmidt A et al (1992) Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6:1634-1641
7. Dreyer C et al (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68: 879-887
8. Berger J, Moller DF (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435
9. Sher T et al (1993) cDNA cloning, chromosomal mapping and functional characterization of human peroxisome proliferator activated receptor. Biochemistry 32:5598-5604
10. Yoshikawa T et al (1996) Assignment of the human nuclear hormone receptor, NUC1 (PPAR delta), to chromosome 6p21.1-p21.2. Genomics 35:637-638
11. Greene ME et al (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4:281-299
12. Bugge A, Mandrup S (2010) Molecular mechanisms and genome-wide aspects of PPAR subtype transactivation. PPAR Res 2010:169506
13. Kliewer SA et al (1992) Convergence of 9-Cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 358:771-774
14. Gearing KL et al (1993) Interaction of peroxisome-proliferator-activated receptor and retinoid x-receptor. Proc Natl Acad Sci USA 90:1440-1444
15. Ijpenberg A et al (1997) Polarity and specific sequence requirements of peroxisome proliferator-activated receptor heterodimer binding to DNA. A functional analysis of the malic enzyme PPAR response element. J Biol Chem 272: 20108-20117
16. Nielsen R et al (2006) Peroxisome proliferatoractivated receptor subtype-and cell-typespecific activation of genomic target genes upon adenoviral transgene delivery. Mol Cell Biol 26:5698-5714
17. Gulick T et al (1994) The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91:11012-11016
18. Wang YX et al (2003) Peroxisome-proliferatoractivated receptor delta activates fat metabolism to prevent obesity. Cell 113:159-170
19. Mueller E et al (2002) Genetic analysis of adipogenesis through peroxisome proliferatoractivated receptor gamma isoforms. J Biol Chem 277:41925-41930
20. Oberkofler H et al (2002) Peroxisome proliferator activated receptor (PPAR) g coactivator-1 recruitment regulates PPAR subtype specificity. J Biol Chem 277:16750-16757
21. Racke M, Drew P (2008) PPARs in neuroinflammation. PPAR Res 2008:638356
22. Calkin AC, Thomas MC (2008) PPAR agonists and cardiovascular disease in diabetes. PPAR Res 2008:245410
23. Duval C et al (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422-430
24. Standiford T, Roman J (2007) PPARs in lung biology and disease. PPAR Res 2007:28765
25. Matthiessen MW et al (2005) Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 40:198-205
26. Pathak R et al (2007) Effect of peroxisome proliferator-activated receptor-alpha agonist (bezafibrate) on gastric secretion and gastric cytoprotection in rats. Fundam Clin Pharmacol 21:291-296
27. Peters JM et al (2008) Role of peroxisomeproliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond) 115: 107-127
28. Kim HS et al (2008) Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/ NeuroD expression. Biochem Biophys Res Commun 367:623-629
29. Masuda K et al (1995) Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24-30
30. Han SJ et al (2008) Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis. Horm Res 70:165-173
31. Holloway AC et al (2008) Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. Diabetes Obes Metab 10:763-771
32. Tanaka T et al (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci (USA) 100:15924-15929
33. Syversen U et al (2009) Different skeletal effects of the peroxisome proliferator activated receptor (PPAR) alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 9:10
34. Still K et al (2008) The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 83:285-292
35. Braissant O et al (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354-366
36. Wang YX et al (2004) Regulation of musclefiber type and running endurance by PPARdelta. PLoS Biol 2:e294
37. de Lange P et al (2008) Peroxisome proliferator-activated receptor delta: a conserved director of lipid homeostasis through regulation of the oxidative capacity of muscle. PPAR Res 2008:172676
38. Narkar VA et al (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134: 405-415
39. Thevis M et al (2010) Characterization of two major urinary metabolites of the PPARdeltaagonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem 396:2479-2491
40. Youssef J, Badr M (2011) PPARs and cancer: challenges and opportunities. Br J Pharmacol 164:68-82